The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes) Trial: To believe or not to believe?

Journal of the American College of Cardiology

Volumn 59, Issue 23, 2012, Pages 2065-2067

  Nicholls, Stephen J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

AIM HIGH; HDL; lipids; niacin; review

Indexed keywords

EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DYSLIPIDEMIA; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTRIGLYCERIDEMIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, HDL; MALE; NIACIN; TRIGLYCERIDES;

EID: 84861648404     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.02.021     Document Type: Review

References (18)

1. C. Baigent, L. Blackwell, J. Emberson Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
2. S. Bansal, J.E. Buring, N. Rifai, S. Mora, F.M. Sacks, P.M. Ridker Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women JAMA 298 2007 309 316
3. S. Erqou, S. Kaptoge, P.L. Perry Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality JAMA 302 2009 412 423
4. T. Gordon, W.P. Castelli, M.C. Hjortland, W.B. Kannel, T.R. Dawber High density lipoprotein as a protective factor against coronary heart disease The Framingham Study Am J Med 62 1977 707 714
5. S.J. Nicholls High-density lipoprotein and progression rate of atherosclerosis in intravascular ultrasound trials Am J Cardiol 104 2009 16E 21E
6. P.L. Canner, K.G. Berge, N.K. Wenger Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255
7. B.G. Brown, X.-Q. Zhao, A. Chait Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592
8. A.J. Taylor, L.E. Sullenberger, H.J. Lee, J.K. Lee, K.A. Grace Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation 110 2004 3512 3517
9. A.J. Taylor, H.J. Lee, L.E. Sullenberger The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3 Curr Med Res Opin 22 2006 2243 2250
10. J.M. Lee, M.D. Robson, L.M. Yu Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study J Am Coll Cardiol 54 2009 1787 1794
11. C.T. Sibley, I. Gottlieb, C. Cox Comparative effect of statins vs niacin on MRI measured regression of carotid atherosclerosis in a randomized clinical trial: the NIA plaque study Circulation 120 2009 S376
12. AIM-HIGH Investigators W.E. Boden, J.L. Probstfield, T. Anderson et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
13. M.H. Luria, D. Sapoznikov Raising HDL cholesterol with low-dose nicotinic acid and bezafibrate: preliminary experience Postgrad Med J 69 1993 296 299
14. P. Barter, A.M. Gotto, J.C. LaRosa HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310
15. H.N. Ginsberg, M.B. Elam, L.C. Lovato Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
16. P.J. Barter, M. Caulfield, M. Eriksson Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
17. E.D. Michos, C.T. Sibley, J.T. Baer, M.J. Blaha, R.S. Blumenthal Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials J Am Coll Cardiol 59 2012 2058 2064
18. B.G. Brown, X.Q. Zhao Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk Am J Cardiol 101 2008 58B 62B